803
Participants
Start Date
December 20, 2017
Primary Completion Date
March 30, 2019
Study Completion Date
June 30, 2019
sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.
Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
Waimaw, Kāchen
Myanmar Liver Foundation Clinic, Mandalay
Myanmar Liver Foundation Charity Clinic, Yangon
Community Partners International
OTHER
Myanmar Liver Foundation
OTHER
Boston University
OTHER
University of California, Los Angeles
OTHER
Ministry of Health and Sports, Myanmar
OTHER_GOV
Right to Care
OTHER